High expression of CREM is associated with poor prognosis in gastric cancer patients

doi:10.12122/j.issn.1673-4254.2024.09.18

Abstract

Abstract:

Objective To analyze the expression of CREM in gastric cancer (GC) and its correlation with prognosis of the patients. Methods TCGA and GEO databases were used to analyze the expression levels of CREM mRNA in GC and adjacent tissues. Immunohistochemistry was used to examine the expression of CREM protein in 43 pairs of GC and adjacent tissues, and the correlation of CREM expression with clinicopathological features of the patients was analyzed. Kaplan-Meier survival analysis was used to explore the relationship between CREM expression and survival of GC patients. LinkedOmics database was used to annotate the GO function and KEGG pathway enrichment of CREM-related genes. Results Database analysis showed that CREM was highly expressed in GC tissues (P<0.05) and positively correlated with poor prognosis in GC patients (P=0.01). Immunohistochemistry results showed significantly higher CREM expression in GC tissues than in paired adjacent tissues (P<0.0001), and its expression level was correlated with T-stage and N-stage of the tumor (P<0.05). The overall survival of GC patients with high expression of CREM was shorter (RR=4.02, P=0.0046). Gene enrichment analysis showed that high CREM expression promotes occurrence and progression of GC very likely through the cell adhesion signaling pathway. Conclusion CREM is highly expressed in GC, and its high expression is associated with a poor prognosis of GC patients, suggesting the potential of CREM to serve as a prognostic indicator for GC.

Key words: gastric cancer, CREM, bioinformatics, immunohistochemistry, prognosis

Mengnan YE, Hongmei WU, Yan MEI, Qingling ZHANG. High expression of CREM is associated with poor prognosis in gastric cancer patients[J]. Journal of Southern Medical University, 2024, 44(9): 1776-1782.

Figures/Tables 6

Fig.1 Differential expression of CREM in different cancers based on data from TCGA-GTEx (A) and TCGA (B) databases. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig.2 Correlation between CREM expression level and Estimate immune infiltration scores in gastric cancer.

Fig.3 CREM is highly expressed in gastric cancer tissues. A: Expression of CREM in gastric cancer and adjacent tissues in TCGA database. B: Differential expression of CREM in tumors in different T-stages. C-E: Differential expression of CREM in gastric cancer tissues and adjacent tissues in GSE65801, GSE63089, and GSE54129 datasets. F, G: Immunohistochemical staining of CREM in gastric cancer and adjacent tissues and the immunohistochemical scores. *P<0.05, ****P<0.0001.

Tab. 1 Relationship between CREM expression and clinicopathological features of 43 patients with STAD

Characteristic	n	CREM Expression		χ²	P
Characteristic	n	Low (n=11)	High (n=32)	χ²	P
Age (year)				1.815	0.178
<60	15	2 (13.3)	13 (86.7)
≥60	28	9 (32.1)	19 (67.9)
Gender				1.120	0.290
Male	29	6 (20.7)	23 (79.3)
Female	14	5 (35.7)	9 (64.3)
Ki-67(%)				1.120	0.290
<50	14	5 (35.7)	9 (64.3)
≥50	29	6 (20.7)	23 (79.3)
Tumor size (cm)				2.516	0.113
<4	15	6 (40.0)	9 (60.0)
≥4	28	5 (17.9)	23 (82.1)
T stage				10.862	0.001
T₁-T₂	14	8 (57.1)	6 (42.9)
T₃-T₄	29	3 (10.3)	26 (89.7)
N stage				4.418	0.036
N₀	16	7 (43.8)	9 (56.2)
N₁-N₃	27	4 (14.8)	23 (85.2)
TNM staging				3.376	0.066
I-II	21	8 (38.1)	13 (61.9)
III-IV	22	3 (13.6)	19 (86.4)

Fig.4 High CREM expression is associated with poor prognosis in gastric cancer patients. A-C: FP, OS, and PPS curves of gastric cancer patients with different CREM mRNA expression levels in the Kaplan-Meier Plotter database. D: OS curves of patients with high and low CREM protein expression in clinical gastric cancer samples.

Fig.5 Analysis of CREM-related genes and results of KEGG and GO enrichment analysis in gastric cancer. A, B: LinkedOmics database analysis of genes positively and negatively correlated with CREM expression in the TCGA gastric cancer dataset. C: GO enrichment analysis to explore the role of CREM in gastric cancer, including the biological process, cellular composition, and molecular function. D: KEGG enrichment analysis to explore the relevant molecular pathways of CREM in gastric cancer development.

References 30

1	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49.
2	Qiu HB, Cao SM, Xu RH. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun, 2021, 41(10): 1037-48.
3	赫捷, 陈万青, 李兆申, 等. 中国胃癌筛查与早诊早治指南(2022，北京)[J]. 中华肿瘤杂志, 2022, 44(7): 634-66.
4	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-91.
5	Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-49.
6	Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy[J]. Gastric Cancer, 2017, 20(1): 175-81.
7	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517): 202-9.
8	Canale M, Casadei-Gardini A, Ulivi P, et al. Epigenetic mechanisms in gastric cancer: potential new therapeutic opportunities[J]. Int J Mol Sci, 2020, 21(15): 5500-9.
9	Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis[J]. Apoptosis, 2003, 8(3): 225-8.
10	Brindle PK, Montminy MR. The CREB family of transcription activators[J]. Curr Opin Genet Dev, 1992, 2(2): 199-204.
11	Sassone-Corsi P. Coupling gene expression to cAMP signalling: role of CREB and CREM[J]. Int J Biochem Cell Biol, 1998, 30(1): 27-38.
12	Sánchez-Jasso DE, López-Guzmán SF, Bermúdez-Cruz RM, et al. Novel aspects of cAMP-response element modulator (CREM) role in spermatogenesis and male fertility[J]. Int J Mol Sci, 2023, 24(16): 12558-67.
13	Wu XM, Jin W, Liu XJ, et al. Cyclic AMP response element modulator-1 (CREM-1) involves in neuronal apoptosis after traumatic brain injury[J]. J Mol Neurosci, 2012, 47(2): 357-67.
14	Kaprio H, Siddiqui A, Saustila L, et al. The oncogenic properties of the EWSR1: CREM fusion gene are associated with polyamine metabolism[J]. Sci Rep, 2023, 13(1): 4884-93.
15	Wang YC, Zhou SH, Yang XJ, et al. Low expression of cyclic AMP response element modulator-1 can increase the migration and invasion of esophageal squamous cell carcinoma[J]. Tumour Biol, 2013, 34(6): 3649-57.
16	Kaprio H, Heuser VD, Orte K, et al. Expression of transcription factor CREM in human tissues[J]. J Histochem Cytochem, 2021, 69(8): 495-509.
17	Shen WT, Song ZG, Zhong X, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform[J]. Imeta, 2022, 1(3): e36.
18	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46.
19	Alsina M, Arrazubi V, Diez M, et al. Current developments in gastric cancer: from molecular profiling to treatment strategy[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(3): 155-70.
20	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-71.
21	Augustin JE, Soussan P, Bass AJ. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma[J]. Ann Oncol, 2022, 33(11): 1134-48.
22	Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(8): 1057-65.
23	Wainberg ZA, Enzinger PC, Kang YK, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study[J]. Lancet Oncol, 2022, 23(11): 1430-40.
24	Qi CS, Gong JF, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-98.
25	Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial[J]. Ann Oncol, 2021, 32(6): 746-56.
26	Servillo G, Della Fazia MA, Sassone-Corsi P. Coupling cAMP signaling to transcription in the liver: pivotal role of CREB and CREM[J]. Exp Cell Res, 2002, 275(2): 143-54.
27	Behr R, Weinbauer GF. cAMP response element modulator (CREM): an essential factor for spermatogenesis in Primates?[J]. Int J Androl, 2001, 24(3): 126-35.
28	Feng F, Wu JT, Gao ZL, et al. Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships[J]. Medicine, 2017, 96(1): e5679.
29	Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: beyond the migration of single cells[J]. J Biol Chem, 2020, 295(8): 2495-505.
30	Chen JZ, Qin HY, Hao JZ, et al. Cardiac-specific overexpression of CREM-IbΔC-X via CRISPR/Cas9 in mice presents a new model of atrial cardiomyopathy with spontaneous atrial fibrillation[J]. Transl Res, 2024, 267: 54-66.

[1]	Xiaohua CHEN, Hui LU, Ziliang WANG, Lian WANG, Yongsheng XIA, Zhijun GENG, Xiaofeng ZHANG, Xue SONG, Yueyue WANG, Jing LI, Jianguo HU, Lugen ZUO. Role of Abelson interactor 2 in progression and prognosis of gastric cancer and its regulatory mechanisms [J]. Journal of Southern Medical University, 2024, 44(9): 1653-1661.
[2]	Kai JI, Guanyu YU, Leqi ZHOU, Tianshuai ZHANG, Qianlong LING, Wenjiang MAN, Bing ZHU, Wei ZHANG. HNRNPA1 gene is highly expressed in colorectal cancer: its prognostic implications and potential as a therapeutic target [J]. Journal of Southern Medical University, 2024, 44(9): 1685-1695.
[3]	Zhijun GENG, Jingjing YANG, Minzhu NIU, Xinyue LIU, Jinran SHI, Yike LIU, Xinyu YAO, Yulu ZHANG, Xiaofeng ZHANG, Jianguo HU. Kuwanon G inhibits growth, migration and invasion of gastric cancer cells by regulating the PI3K/AKT/mTOR pathway [J]. Journal of Southern Medical University, 2024, 44(8): 1476-1484.
[4]	Yidan PANG, Ya LIU, Siai CHEN, Jinglei ZHANG, Jin ZENG, Yuanming PAN, Juan AN. Biological role of SPAG5 in the malignant proliferation of gastric cancer cells [J]. Journal of Southern Medical University, 2024, 44(8): 1497-1507.
[5]	Hongli YANG, Yayun XIANG, Tingting TAN, Yang LEI. ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway via suppressing lysine-specific demethylase 1 expression [J]. Journal of Southern Medical University, 2024, 44(8): 1620-1630.
[6]	Wei ZHOU, Jun NIE, Jia HU, Yizhi JIANG, Dafa ZHANG. Differential expressions of endoplasmic reticulum stress-associated genes in aortic dissection and their correlation with immune cell infiltration [J]. Journal of Southern Medical University, 2024, 44(5): 859-866.
[7]	Yongsheng XIA, Lian WANG, Xiaohua CHEN, Yulu ZHANG, Aofei SUN, Deli CHEN. TSR2 overexpression inhibits proliferation and invasion of gastric cancer cells by downregulating the PI3K/AKT signaling pathway [J]. Journal of Southern Medical University, 2024, 44(5): 913-919.
[8]	Bei PEI, Yi ZHANG, Siyuan WEI, Yu MEI, Biao SONG, Gang DONG, Ziang WEN, Xuejun LI. Identification of potential pathogenic genes of intestinal metaplasia based on transcriptomic sequencing and bioinformatics analysis [J]. Journal of Southern Medical University, 2024, 44(5): 941-949.
[9]	Jingjing YANG, Lixia YIN, Ting DUAN, Minzhu NIU, Zhendong HE, Xinrui CHEN, Xiaofeng ZHANG, Jing LI, Zhijun GENG, Lugen ZUO. High expression of ATP5A1 in gastric carcinoma is correlated with a poor prognosis and enhanced glucose metabolism in tumor cells [J]. Journal of Southern Medical University, 2024, 44(5): 974-980.
[10]	Qinzhi WANG, Bing SONG, Shirui HAO, Zhiyuan XIAO, Lianhui JIN, Tong ZHENG, Fang CHAI. Bioinformatic analysis of CCND2 expression in papillary thyroid carcinoma and its impact on immune infiltration [J]. Journal of Southern Medical University, 2024, 44(5): 981-988.
[11]	LIANG Yihao, LAI Yingjun, YUAN Yanwen, YUAN Wei, ZHANG Xibo, ZHANG Bashan, LU Zhifeng. Screening of differentially expressed genes in gastric cancer based on GEO database and function and pathway enrichment analysis [J]. Journal of Southern Medical University, 2024, 44(3): 605-616.
[12]	SHEN Mengdi, ZHAO Na, DENG Xiaojing, DENG Min. High expression of COX6B2 in gastric cancer is associated with poor long-term prognosis and promotes cell proliferation and cell cycle progression by inhibiting p53 signaling [J]. Journal of Southern Medical University, 2024, 44(2): 289-297.
[13]	ZHANG Nuo, ZHANG Zhen, ZHANG Yulu, SONG Xue, ZHANG Xiaofeng, LI Jing, ZUO Lugen, HU Jianguo. PCID2 is highly expressed in gastric cancer and affects the prognosis by regulating cancer cell cycle and proliferation [J]. Journal of Southern Medical University, 2024, 44(2): 324-332.
[14]	ZHANG Wenjing, ZHANG Nuo, YANG Zi, ZHANG Xiaofeng, SUN Aofei, WANG Lian, SONG Xue, GENG Zhijun, LI Jing, HU Jianguo. Overexpression of BZW1 promotes invasion and metastasis of gastric cancer cells by regulating Wnt/β-catenin signaling and promoting epithelial-mesenchymal transition [J]. Journal of Southern Medical University, 2024, 44(2): 354-362.
[15]	CHENG Jiacong, LI Zhihui, LIU Yao, LI Cheng, HUANG Xin, TIAN Yinxin, SHEN Fubing. Bioinformatics analysis and validation of the interaction between PML protein and TAB1 protein [J]. Journal of Southern Medical University, 2024, 44(1): 179-186.